LP-168 tablet

DRUG3 trials

Sponsors

Guangzhou Lupeng Pharmaceutical Company LTD.

Conditions

B-cell LymphomaMantle Cell LymphomaMultiple SclerosisNMO Spectrum Disorder

Phase 1

A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

RecruitingNCT04993690

Guangzhou Lupeng Pharmaceutical Company LTD.B-cell Lymphoma

Start: 2021-07-06End: 2027-09-30Target: 200Updated: 2026-09-14

A Study of LP-168 in Healthy Volunteers

CompletedNCT05432713

Guangzhou Lupeng Pharmaceutical Company LTD.Multiple Sclerosis, NMO Spectrum Disorder

Start: 2022-05-14End: 2022-12-28Updated: 2023-02-24

A Food Effect Study of LP-168 Tablets in Healthy Subjects

CompletedNCT05917964

Guangzhou Lupeng Pharmaceutical Company LTD.Mantle Cell Lymphoma

Start: 2023-06-21End: 2023-08-21Updated: 2023-09-11

Related Papers

Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study.

2026-07-24

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Blood2025-11-03

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood2025-11-03

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Blood2025-11-03

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Blood2024-11-051 citations

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood2024-11-05

A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study

Blood2023-11-025 citations

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

Blood2023-11-024 citations

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood2023-11-02